On Tuesday, Wabash National Corporation (NYSE:WNC)’s shares declined -1.34% to $13.21.
Wabash National Corporation (WNC) declared that it has accomplished an amendment to its credit agreement with a group of lenders that provides the Company’s $150.0 million, asset-based, revolving credit facility. Among other things, the amendment will i) extend the maturity of the facility from May, 2017, to June, 2020; ii) provide for an enhance in committed capital from the Company’s lenders of $25 million, to $175 million; iii) reduce interest rate margins by 25 basis points on borrowings; and, iv) reduce the unused line fee by 12.5 basis points to 25 basis points.
Wabash National Corporation designs, manufactures, and markets truck and tank trailers, intermodal equipment, and transportation related products in North America. Its Commercial Trailer Products segment provides dry van trailers under the DuraPlate, DuraPlateHD, DuraPlate, XD-35, and FreightPro trademarks; platform trailers under the Transcraft, Eagle, and Benson trademarks; refrigerated trailers under the ArcticLite trademark; and specialty products, such as converter dollies, big tire haulers, Roadrailer trailers, rail products, aftermarket component products, parts, and others, in addition to used trailers and laminated hard wood oak products.
Central Pacific Financial Corp. (NYSE:CPF)’s shares gained 0.30% to $23.08.
Central Pacific Financial Corp. (CPF) declared the resignations of directors Alvaro J. Aguirre and James F. Burr from the boards of the Company and the Bank, effective recently. In an earlier declarement made by the Company, Catherine Ngo and Lance Mizumoto will be designated to the boards of the Company and the Bank, effective July 1, 2015.
Aguirre and Burr joined the boards of CPF and CPB in 2011 as directors and designees of Anchorage Advisors, L.L.C. (Anchorage) and Carlyle Financial Services Harbor, L.P. (Carlyle), respectively, when the Company accomplished its recapitalization initiative with Anchorage and Carlyle as the co-lead investors. Anchorage and Carlyle have been divesting their ownership in the Company since April, 2014, and each holds about 8.8% of CPF’s issued and outstanding common stock following their most recent sale that closed on June 10, 2015, in an underwritten secondary offering.
Central Pacific Financial Corp. operates as the holding company for Central Pacific Bank that provides commercial banking products and services to businesses, professionals, and individuals in Hawaii. The company operates in three segments: Banking Operations, Treasury, and All Others. It offers various deposit products and services, counting personal and business checking and savings accounts, money market accounts, and time certificates of deposit.
At the end of Tuesday’s trade, CME Group Inc (NASDAQ:CME)‘s shares surged 0.30% to $96.53.
CME Group Inc (CME) the world’s leading futures exchange - and the National 4-H Council – America’s largest youth development organization are partnering for a third successive year to bring their popular and award-winning Commodity Carnival fair experience to more than 100 state and county fairs in nine states this summer. An interactive and educational game about the business of agriculture, the Commodity Carnival teaches young fairgoers how to manage the costs and risks associated with bringing an animal - this year, a hog - to market. Beyond the fairgrounds and throughout the year, the Commodity Carnival mobile app, Risk Ranch, enables people of all ages to try their hand at agricultural risk administration from their mobile devices, in addition to online.
CME Group Inc., through its auxiliaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers a range of products for trading and/or clearing across various asset classes, based on interest rates, equity indexes, foreign exchange, energy, agricultural commodities, and metals. The products comprise exchange-traded; and privately negotiated futures and options contracts and swaps.
bluebird bio Inc (NASDAQ:BLUE), ended its Tuesday’s trading session with -4.83% loss, and closed at $170.64.
bluebird bio Inc (BLUE) a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies, recently declared long-term follow up of two patients with beta-thalassemia major and early safety and efficacy data in the first patient with severe sickle cell disease (SCD) treated with LentiGlobin BB305 product candidate in the HGB-205 study. These data were presented recently at the 20th Congress of the European Hematology Association (EHA) in Vienna, Austria by Marina Cavazzana, M.D., Ph.D., lead investigator of the HGB-205 study and professor of hematology at Paris Descartes University, head of the department of Biotherapy Hospital, the clinical research INSERM center of Biotherapy at Necker Enfants Malades, (Assistance Publique-Hôpitaux de Paris) and the Lymphohematopoiesis Laboratory, Institute of Genetic Diseases, Imagine, Paris, France.
Key findings:
- Beta-thalassemia:
- As of May 2015, Subjects 1201 and 1202 with beta-thalassemia major remained transfusion-independent for 16 and 14 months, respectively, with persistent stable expression of HbAT87Q. Neither has practiced a LentiGlobin-related adverse event.
- Sickle Cell Disease:
- Theproportion of anti-sickling hemoglobin being produced by the first-ever patient with severe SCD treated with gene therapy (Subject 1204) is rising steadily and accounted for 45% of all hemoglobin production (40% HbAT87Q + 5% HbF) at the patient’s six-month visit post-drug product infusion; this is above the 30% threshold predictable to potentially achieve a disease-modifying clinical effect.
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic and rare diseases. Its advanced product candidate is Lenti-D, which is in phase II/III clinical studies for the treatment of childhood cerebral adrenoleukodystrophy, a rare, hereditary neurological disorder affecting young boys; and LentiGlobin that is in phase I/II clinical studies for the treatment of beta-thalassemia major and severe sickle cell disease (SCD) in France, in addition to a phase I study in the United States for the treatment of severe SCD.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
